Rheumatology

Sint Nicolaasga, Netherlands

Rheumatology

Sint Nicolaasga, Netherlands

Time filter

Source Type

CrowdReviews.com Partnered with Madridge Conferences to Announce International Conference on Immunology and Immunotechnology Immunology-2017 features highly enlightening and interactive sessions to encourage the exchange of ideas across a wide range of disciplines in the field of immunology. Immunology-2017 mainly showcases comprehensive approaches in immunology study and research. The field of Immunology is growing rapidly and its development is making tremendous impacts in medical sciences. Immunology-2017 invites the contributions related to immunology research. You can submit your work in these broad themes. Conference mainly focuses on: Clinical and cellular immunology Tumour and cancer immunology Neuro immunology Parasitology Autoimmunity and Therapathies Mucosal immunology Reproductive Immunology Immunobiology Infection & Inflammatory Disease Rheumatology Haematopoiesis Transplantation Immunology Virology Immunodermatology Molecular and Structural Immunology Veterinary Immunology and Immunopathology Allergology and Immunology All the abstracts should be submitted through Immunology-2017 Speakers: · Nadir Kadri, Karolinska Institute, Sweden · Pawel Gajdanowicz, Wroclaw Medical University, Poland · Joel Babdor, Stanford University School of Medicine, USA · Kwan Chow, Washington University, USA · Abdallah Badou, Cadi Ayyad University, Morocco Immunology-2017 Organizing Committee: · Carmen Fernández , Stockholm University, Sweden · Carl Borrebaeck, Lund University, Sweden · SY Seong, Seoul National University College of Medicine, South Korea · Shi, Guo-Ping, Brigham and Women's Hospital, USA · Gideon Berke, Weizmann Institute of Science, Isreal · Eyad Elkord, United Arab Emirates University, United ArabEmirates · Noah Isakov, Ben Gurion University of the Negev, Isreal · Joel Pomerantz, The Johns Hopkins University School of Medicine, USA · NanShan Chang, Institute of Molecular Medicine, Taiwan · Hisaya Akiba, Juntendo University School of Medicine, Japan · Ricardo Luiz Dantas Machado, Evandro Chagas Institute, Brazil Immunology-2017 is organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in Immunology Research. They welcome Sponsorship and Exhibitions from the Companies and Organizations who wish to showcase their products at this exciting event. Register for the conference and book your slots at: Contact person: Sumanjani immunology@madridge.com immunology@madridge.net Naples, FL, May 09, 2017 --( PR.com )-- International Conference Immunology and Immunotechnology is going to be held during November 1-3, 2017 in Barcelona, Spain.Immunology-2017 features highly enlightening and interactive sessions to encourage the exchange of ideas across a wide range of disciplines in the field of immunology. Immunology-2017 mainly showcases comprehensive approaches in immunology study and research. The field of Immunology is growing rapidly and its development is making tremendous impacts in medical sciences.Immunology-2017 invites the contributions related to immunology research. You can submit your work in these broad themes.Conference mainly focuses on:Clinical and cellular immunologyTumour and cancer immunologyNeuro immunologyParasitologyAutoimmunity and TherapathiesMucosal immunologyReproductive ImmunologyImmunobiologyInfection & Inflammatory DiseaseRheumatologyHaematopoiesisTransplantation ImmunologyVirologyImmunodermatologyMolecular and Structural ImmunologyVeterinary Immunology and ImmunopathologyAllergology and ImmunologyAll the abstracts should be submitted through online abstract submission or can be mailed at immunology@madridge.com Immunology-2017 Speakers:· Nadir Kadri, Karolinska Institute, Sweden· Pawel Gajdanowicz, Wroclaw Medical University, Poland· Joel Babdor, Stanford University School of Medicine, USA· Kwan Chow, Washington University, USA· Abdallah Badou, Cadi Ayyad University, MoroccoImmunology-2017 Organizing Committee:· Carmen Fernández , Stockholm University, Sweden· Carl Borrebaeck, Lund University, Sweden· SY Seong, Seoul National University College of Medicine, South Korea· Shi, Guo-Ping, Brigham and Women's Hospital, USA· Gideon Berke, Weizmann Institute of Science, Isreal· Eyad Elkord, United Arab Emirates University, United ArabEmirates· Noah Isakov, Ben Gurion University of the Negev, Isreal· Joel Pomerantz, The Johns Hopkins University School of Medicine, USA· NanShan Chang, Institute of Molecular Medicine, Taiwan· Hisaya Akiba, Juntendo University School of Medicine, Japan· Ricardo Luiz Dantas Machado, Evandro Chagas Institute, BrazilImmunology-2017 is organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in Immunology Research. They welcome Sponsorship and Exhibitions from the Companies and Organizations who wish to showcase their products at this exciting event.Register for the conference and book your slots at: http://immunology.madridge.com/register.php Contact person:Sumanjani


Dr Kwon, medisch directeur bij Celltrion Healthcare, verklaarde: “ De publicatie van de NOR-SWITCH-gegevens in The Lancet markeert opnieuw een belangrijke mijlpaal voor het vergroten van het vertrouwen van artsen om biosimilar infliximab te gebruiken als overwogen wordt om hun patiënten over te schakelen.” Na presentaties tijdens zowel de 2016 United European Gastroenterology (UEG) Week als de jaarlijkse bijeenkomst van het American College of Rheumatology (ACR) bleek uit de bevindingen van de studie dat van de 50% van de patiënten die overgeschakeld waren naar CT-P13, het percentage patiënten met verslechtering van de ziekte vergelijkbaar was met die patiënten die referentie infliximab bleven gebruiken (respectievelijk 29,6 en 26,2%). De datadiscontinueringspercentages door een gebrek aan werkzaamheid voor referentie infliximab en biosimilar infliximab waren respectievelijk acht en drie. De tijd om de stopzetting van de medicijnen te onderzoeken was bijna identiek tussen de twee groepen, waarbij ook vergelijkbare totale remissiecijfers en frequenties van bijwerkingen waargenomen werden. 1 CP-P13 is ontwikkeld en geproduceerd door Celltrion, Inc. en was 's werelds eerste monoklonaal antilichaam-biosimilar dat werd goedgekeurd door het Europees Geneesmiddelenbureau (EMA). Het is geïndiceerd voor de behandeling van acht auto-immuunziekten zoals reumatoïde artritis en inflammatoire darmziekte. Het werd in september 2013 door de EMA goedgekeurd onder de handelsnaam Remsima® goedgekeurd en begin 2015 gelanceerd in Europa. De Amerikaanse FDA keurde Celltrion's CT-P13 goed in april 2016 onder de handelsnaam Inflectra™. Celltrion's CT-P13 is goedgekeurd in meer dan 79 (vanaf januari 2017) landen, waaronder de VS, Canada, Japan en heel Europa. Celltrion Healthcare voert wereldwijde marketing, verkoop en distributie van biologische geneesmiddelen ontwikkeld door Celltrion, Inc. uit via een uitgebreid wereldwijd netwerk dat meer dan 120 verschillende landen bestrijkt. De producten van Celltrion Healthcare worden gemaakt in state-of-the-art faciliteiten voor zoogdiercelcultuur, ontworpen en gebouwd om te voldoen aan de Amerikaanse cGMP-normen van de FDA en de GMP-normen van de EU. Voor meer informatie kunt u terecht op: http://www.celltrionhealthcare.com/ The Lancet is een van 's werelds grootste onafhankelijke algemene medische tijdschriften. Het intercollegiaal getoetste tijdschrift publiceert medisch nieuws en origineel onderzoek en biedt evaluaties over alle aspecten van klinische geneeskunde en internationale gezondheid. The Lancet heeft een impactfactor van 44,002. 1 Jørgensen, K. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. The Lancet, beschikbaar op: http://dx.doi.org/10.1016/S0140-6736(17)30068-5 [geraadpleegd in mei 2017]. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.


News Article | April 24, 2017
Site: www.eurekalert.org

The EULAR Annual European Congress of Rheumatology is the foremost international medical meeting announcing the latest research on rheumatic and musculoskeletal diseases. EULAR 2016 attracted over 14,000 delegates from 120 countries, most if not all professions working with rheumatology were represented. To hear the latest news on the full spectrum of rheumatic and musculoskeletal diseases - including clinical symposia, abstract sessions, presentations and workshops - register now. Press registration is free of charge for all holders of formal journalist credentials. Press will have access to the official Press Conferences and onsite press facilities, including a working room and dedicated interview areas. The Press Office will also be able to assist you in organising interviews with the EULAR leadership and relevant experts. All registered journalists (whether attending the congress in person or working remotely) will receive access to digital press packs, media e-alerts, access to official Press Conference presentations online and expert interview coordination. We look forward to seeing you in Madrid!


News Article | May 4, 2017
Site: www.eurekalert.org

A new study estimates that the lifetime risk of symptomatic hand osteoarthritis is 40%, and nearly one in two women and one in four men will develop the condition, which affects hand strength and function and causes disability in activities of daily living. Race-specific estimates are 41% among whites and 29% among blacks. Also, the lifetime risk among individuals with obesity is 47%, which is 11 percentage points higher than those without obesity. These findings indicate that hand osteoarthritis is very common. In comparison, prior studies have estimated lifetime risks for symptomatic knee and hip osteoarthritis to be 45% and 25%, respectively. "These findings demonstrate the substantial burden of symptomatic hand osteoarthritis overall and in subgroups. Increased use of public health and clinical interventions is needed to address its impact," wrote the authors of the Arthritis & Rheumatology study.


ATLANTA - The American College of Rheumatology's President, Sharad Lakhanpal, MBBS, MD, released a statement today in response to the U.S. House of Representatives passing the American Health Care Act (AHCA). In the response, Lakhanpal expressed concern over the MacArthur amendment, states being able to opt out of essential coverage, and the $8 billion funding for high-risk pool being an insufficient, short-term fix. "If enacted in its current form, the legislation would make it harder for our patients to access the care they need to manage pain, avoid long-term disability, remain active in the workforce, and preserve their quality of life, " said Lakhanpal. "Changes made to the bill in recent weeks - specifically those outlined in the MacArthur Amendment - would allow states to opt out of many of the crucial consumer protections the ACA provides to chronic disease patients, including essential health benefits, the ban on health status underwriting, and the 3-to-1 age rating ratio. If states waive these protections, healthcare coverage will become unaffordable for individuals with pre-existing conditions like arthritis, and may lead to discrimination against individuals with certain high-cost medical conditions. "Furthermore, the $8 billion in additional funding for high-risk pools is a short-term fix for people with life-long care needs. High-risk pools have been historically underfunded, and chronically ill patients seeking this type of coverage regularly experience soaring deductibles and premiums. Without an official score from the Congressional Budget Office, there is no way to assess whether the additional funding would be enough to offset coverage losses for people living with arthritis." The ACR has outlined specific provisions that would need to be included in any replacement bill to ensure Americans have continued access to rheumatologic care. The complete statement is available on the ACR website. The American College of Rheumatology (ACR) is the nation's leading advocacy organization for the rheumatology care community, representing more than 9,500 rheumatologists and rheumatology health professionals. As an ethically driven, professional membership organization committed to improving healthcare for Americans living with rheumatic diseases, the ACR advocates for high-quality, high-value policies and reforms that will ensure safe, effective, affordable and accessible rheumatology care.


News Article | April 10, 2017
Site: www.techtimes.com

Ticked Off! Here's What You Need To Know About Lyme Disease As this year’s tick season shapes up to be a ruthless one, different regions in the United States are gearing up for a potentially greater prevalence of Lyme disease and other tick-borne conditions. A warm February this year gave ticks an early head start this year, even when spring has just started. Bruce Shilton, formerly a lawyer and Newmarket court judge, looks back at the tick bite that gave him Lyme disease about 20 years ago and has changed his life since. Back in 1998, Shilton was bitten by a black-legged tick and made him sick with Lyme, with the effects manifesting today in his liver, gall bladder, and kidneys. While no longer stuck with excruciating pain, he shared about no longer being able to think clearly and get through the day without massive fatigue and bouncing from one doctor and failed treatment to another. “I’ve been to just about every specialist out there. You run out of inventory. You see a chronic fatigue specialist, an endocrinologist, a nephrologist, a cardiologist… You finally end up with a psychiatrist and they say, ‘you’ve probably got depression,’” he told YorkRegion. He had to hazard a guess: every Lyme disease patient likely has “secondary depression” from his or her disappearing life and the brunt of costly yet ineffective treatments. In 2015, Shilton thought he was improving, and he was fueled by hopes of returning to his successful law career. But he suddenly regressed and became housebound once again. Today while he keeps trying different therapies such as essential oils and homeopathic pellets from abroad, he is still stumped two years after a private members bill was passed in Ontario Legislature, mandating a so-called “Lyme Action Plan.” There are a number of developments — such as nonprofits like Global Lyme Alliance raising funds for research — but there’s still no clinical testing over alternative treatments, he added. “It’s pretty sad,” the former courtroom judge mourned. “Boredom is brutal, when you go from my old life to this.” Lyme disease is characterized by rashes, swollen knees, and facial paralysis. It is a difficult disease to diagnose, and when left untreated could lead to severe conditions including memory loss, chronic arthritis, and heart rhythm irregularities. Remaining one of the most common kinds of vector-borne diseases in the country, it has recently made an early appearance in the East Coast, with climate change suspected to be an underlying factor. June and July, according to Dr. John Aucott of the Johns Hopkins Rheumatology Lyme Disease Research Center in Baltimore, are the usual months when Lyme arrives. At this time, ticks are still at an undeveloped stage and can move from one wild host to dogs and humans. Now, with climatic variations, Lyme is seen to be stronger, with rising temperatures playing a role in the reproduction of mice. These creatures are the known homes of the Borrelia burgdoferi carrying the disease, as well as the tick spreading the infection to humans. Mice also better multiply with the cutting down of trees and the fragmentation of forests for building homes and industrialization, experts warned. There are several proper ways to deal with tick bites, especially as not all black-legged ticks are infected with Lyme. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.


Ticked Off! Here's What You Need To Know About Lyme Disease Ticks are usually a bigger scourge in the warmer months as humans and pets alike spend more time outdoors and have a greater chance of bringing home these insects. But given a warm February, ticks appear to get an early head start this year, even when spring has just begun. Along with an earlier, worse tick season is a foreseen greater prevalence of Lyme disease and other tick-borne conditions in different regions. "Spring is the worst time because the nymphs come out, and the nymphs versus an adult are very small, and they can bite you, but they are just much, much harder to see," Dr. Christopher Grace, infectious disease specialist at the University of Vermont Medical Center, told WCAX. Lyme disease, among the most common kinds of vector-borne diseases in the country, has made an early appearance in the East Coast. And experts pointed to climate change for the dangerous trend. According to Dr. John Aucott, who heads the Johns Hopkins Rheumatology Lyme Disease Research Center in Baltimore, June and July are the usual months when Lyme disease arrives. During this window, the ticks — still at an undeveloped phase — can move from a wild host to dogs and humans. Climate events such as rising temperatures are deemed one of the strongest reasons behind the reproduction of mice, which are home for the disease-carrying Borrelia burgdorferi, the tick spreading infections to humans. The cutting down of trees, too, appear to result in fragmented forests, which feed into conditions supporting the multiplication of mice. Ticks, the tiny eight-legged creatures feeding on blood, are also now living year-round since the last couple of years. “I’ve seen more ticks on dogs in the last two and a half years than I have in the last 15 years of practice. They’re really becoming a hazard,” said veterinarian Clayton Greenway, citing climate change and urban expansion as factors behind their increase in numbers. In the last half-century, scientists found at least a dozen new tick-borne conditions. There’s anaplasmosis, babesiosis, and a Lyme-similar bacterium in the Northeast, while the Midwest deals with concerns like Lyme-like Heartland virus and Bourbon virus. The South is documented to be battling Southern tick-associated rash illness, while the West has detected a new kind of spotted fever. Powassan virus, which was named after a Canadian town and discovered in 1958, is particularly concerning for experts given it’s a deadly one transmitted by the local blacklegged tick. It attacks the brain, swells it up, and leads to a 50 percent likelihood of permanent neurological damage even upon recovery. One can implement ways to address tick bites properly or prevent them in the first place, as well as spot Lyme disease early on. People affected with Lyme suffer from locally erupting rashes, swollen knees, and facial paralysis. It is a difficult disease to treat and, when left untreated, may trigger severe conditions such as memory loss, chronic arthritis, and irregularities in heart rhythm. When removing a tick during a bite, it is important to leave the creature’s body intact. Avoid squeezing it or lighting a match under its body. Afterward, you may take a picture of the tick and send it to the TickEncounter Resource Center for identification. If you are living in a high-risk area, visit a doctor if you see the notable red rash showing up. It may not be the same famous shape all the time; it could also be normal-looking that continues to grow. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.


News Article | May 5, 2017
Site: www.prweb.com

Friday, May 5, 2017, the Directors of Health Promotion & Education (DHPE) completes its tour of all five regions of the Chi Eta Phi Sorority at the 64th Annual Southwest Regional Conference, South Point Casino and Hotel, 9777 Las Vegas Blvd South, Las Vegas, NV. “With the average diagnosis timeframe being 4 to 6 years, lupus patients need more health care providers to know and recognize the signs and symptoms of lupus to decrease the diagnosis timeframe and help lupus patients have better health outcomes,” said DHPE Lupus Education and Awareness for Patients, Professionals and Providers (LEAP) Program Director Thometta Cozart, MS, MPH, CHES, CPH. Lupus is a chronic, autoimmune disease with no cure that can damage any part of the body, including skin, joints and organs. Current research shows that at least 1.5 million Americans have lupus, per the Lupus Foundation of America. Women of color are two to three times more likely to develop lupus than Caucasians. “Lupus is a difficult disease to diagnosis and this partnership with the DHPE LEAP will ensure our professional nurse membership is better prepared to address lupus health disparities, such as late diagnosis among women of color that may lead to organ failure and premature death,” said Chi Eta Phi National Vice President Priscilla J. Murphy LPCMH, MEd, BSN, RN, and owner of Nylex Educational & Counseling Services, Inc. According to the American College of Rheumatology, lupus patients see at least three providers, including nurses, before receiving an accurate lupus diagnosis. Lupus educational sessions featuring rheumatologists, lupus researchers and lupus patients will be coordinated by DHPE LEAP and hosted at the regional meetings of Chi Eta Phi Sorority, Inc. to educate more nurses on the signs and symptoms of lupus for more accurate diagnosis. DHPE’s Lupus Education and Awareness for Patients, Professionals and Providers [LEAP] Program Session is scheduled for Friday, May 5, 2017. It will be opened by Thometta Cozart, MS, MPH, CHES, CPH, LEAP Program Director and features: Irene Blanco, MD, MS, Associate Dean of Diversity Enhancement, Rheumatology Fellowship Program Director, Einstein College of Medicine and Lupus Patient Advocate Hetlena Johnson, Chief Volunteer Officer of South Carolina Community Partner, an affiliate of the Lupus Foundation of America, Inc. The session will educate on the signs and symptoms of lupus; the descriptive epidemiological assessment of the disease; case studies and the patient-provider perspective. Established in October 16, 1932, Chi Eta Phi has more than 8,000 sorority members in graduate and undergraduate chapters grouped into five regions based on geographic areas. The chapters are located throughout the United States, District of Columbia, St. Thomas U.S. Virgin Island and Liberia, West Africa. The Sorority has programs focusing on health promotion/disease prevention, leadership development, mentoring, recruitment and retention and scholarships. The partnership is part of the DHPE LEAP Program, which is funded by the national Office of Minority Health, US Department of Health and Human Services. The program targets women of color who are at an increased risk for lupus, as well as educating public health professionals and primary care providers of the signs and symptoms of lupus. The LEAP Program also has national partnerships with the National Medical Association and the National Black Nurses Association. For more program information contact LEAP Project Director Thometta Cozart at tcozart@dhpe.org and visit the program website at http://www.bit.ly/dhpelupus. The Directors of Health Promotion and Education (DHPE) is a national non-profit organization whose mission is to build on principles and practices of health promotion and education to strengthen public health capacity in policy and systems change, thereby improving the health of all and achieving health equity. DHPE, founded in 1946, is legally known as the Association of State and Territorial Directors of Health Promotion and Public Health Education (ASTDHPPHE). DHPE is located at 1030 15th Street NW, #275, Washington, DC 20005. For more information, visit http://www.dhpe.org.


-- Increased Investment in its Rapidly Growing Orphan Biologic Medicine for Refractory Chronic Gout, KRYSTEXXA® -- -- Raising KRYSTEXXA Peak Annual Net Sales Estimate to More than $400 Million from More than $250 Million -- -- Announces Acquisition of River Vision Development Corp. and Teprotumumab, a Biologic in Late-Stage Development for a Rare Eye Disease -- -- Revising Full-Year 2017 Net Sales Guidance Range to $1.000 Billion to $1.035 Billion and Full-Year 2017 Adjusted EBITDA Guidance Range to $315 Million to $350 Million; Reflects Revisions to the Primary Care Business Unit Assumptions, Increased Investment in KRYSTEXXA and R&D Investment in Teprotumumab -- -- Announces Board of Directors’ Authorization of Share Repurchase Program for Approximately 10 Percent of Shares Outstanding -- DUBLIN, Ireland, May 08, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its first-quarter 2017 financial results today and revised its full-year 2017 net sales and adjusted EBITDA guidance. “We generated strong first-quarter performance in our orphan and rheumatology business units, with KRYSTEXXA and RAVICTI achieving record net sales; however, our primary care business unit performed well below our expectations,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc.  “The lower primary care business unit results were related to the implementation of the contracting model with pharmacy benefit managers, which has not performed in accordance with our expectations.  While we are proactively addressing this underperformance, with greater visibility into the impact of this transition, we are revising our full-year 2017 net sales and adjusted EBITDA guidance.” Mr. Walbert added, “We have transformed Horizon Pharma into a company focused on rare disease medicines and we are significantly increasing our investment in one of our key growth drivers, KRYSTEXXA, which we now believe can exceed $400 million in peak annual sales.  That investment is supported by our continued expectation of strong cash-flow generation for the year, which also allows us to continue to seek attractive acquisitions, such as River Vision, which we announced today.  These actions, in addition to our newly authorized share repurchase program, reflect our confidence in the long-term value of our Company.” • Orphan Business Unit:  First-quarter orphan business unit net sales increased 70 percent compared to the first quarter of 2016. RAVICTI net sales in the first quarter of 2017 were $43.9 million, an increase of 18 percent compared to the first quarter of 2016.  The Company expects RAVICTI to be launched in Europe later in 2017 in partnership with Swedish Orphan Biovitrum AB (SOBI). PROCYSBI net sales in the first quarter of 2017 were $34.3 million, up 25 percent compared to Raptor’s pre-acquisition net sales of $27.5 million in the first quarter of 2016, driven by continued strong patient demand from both patients converting from older-generation therapy as well as treatment-naïve patients. ACTIMMUNE net sales in the first quarter of 2017 were $26.2 million, an increase of 3 percent versus the first quarter of 2016.  The Company has evolved its strategy to establish the role of ACTIMMUNE in a broader range of chronic granulomatous disease patients and ACTIMMUNE remains on track to return to growth for the full-year 2017. The Company continues to make progress in the Phase 1 dose escalation trial evaluating ACTIMMUNE as part of a combination therapy in solid tumors for certain cancers.  In February, preliminary data presented at the American Society of Clinical Oncology Clinical Immuno-Oncology Symposium conference showed that combination therapy of ACTIMMUNE with nivolumab, a PD-1 inhibitor, was safe and well-tolerated in the first two cohorts.  The data also showed statistically significant activation of certain monocytes, or white blood cells in peripheral blood, which demonstrates that ACTIMMUNE is having the desired effect of stimulating immune cells.  These are early results, and the third cohort of patients is still under study.  In the first quarter of 2017, a fourth cohort was added to the study to more fully assess dose response.  In addition, a number of academic and clinical institutions have expressed interest in studying ACTIMMUNE as combination therapy in certain cancers, including the National Cancer Institute, which plans to initiate a study later this year to treat patients with Cutaneous T-Cell Lymphoma (CTCL) with ACTIMMUNE and pembrolizumab, a PD-1 inhibitor. The acquisition of River Vision provides the Company with teprotumumab, a fully human monoclonal antibody that targets Insulin-like Growth Factor-1 receptor (IGF-1R).  Teprotumumab is in late-stage development for TED, and has received Orphan Drug, Fast Track and Breakthrough Therapy designations from the FDA.  On May 4, 2017, The New England Journal of Medicine published teprotumumab Phase 2 study results that demonstrate significant clinical efficacy in TED.  Teprotumumab was also safe and well tolerated.  The Company expects to begin a Phase 3 pivotal program of teprotumumab in TED in the second half of 2017. • Rheumatology Business Unit:  KRYSTEXXA net sales in the first quarter of 2017 were $31.6 million, an increase of 96 percent compared to the first quarter of 2016.  Since acquiring the medicine in January of 2016, the Company’s improved commercial strategy and additional investment in commercial, education and outreach efforts has rapidly accelerated KRYSTEXXA net sales. Based on the continued increase in uptake of KRYSTEXXA and the clear unmet need that exists for thousands of refractory chronic gout sufferers, the Company will significantly increase its infrastructure and investment in the medicine.  Beginning in the second quarter and continuing through the second half of 2017, the Company will expand its commercial organization to nearly 200 employees from more than 100.  With the additional resources, the Company expects to expand its reach to physicians and increase awareness of refractory chronic gout among physicians and patients.  As a result, the Company now expects KRYSTEXXA annual peak net sales of more than $400 million versus the previous estimate of more than $250 million. • Primary Care Business Unit:  Total net sales for the primary care business unit were $65.6 million in the first quarter of 2017.  Net sales of PENNSAID 2%, DUEXIS and VIMOVO in the first quarter of 2017 were $41.6 million, $17.7 million and $4.9 million, respectively. During the second half of 2016, the Company entered into rebate agreements with pharmacy benefit managers (PBMs) in an effort to secure broader inclusion of its primary care medicines on healthcare plan formularies.  This transition to PBM rebate agreements, most of which became effective January 1, 2017, was a change to the commercial model of the Company’s primary care business unit, and following this transition, first-quarter 2017 primary care business unit net sales were lower than the Company’s expectations. Total prescription volumes for DUEXIS, VIMOVO and PENNSAID 2% were approximately in line with the Company’s expectations in the first quarter of 2017.  However, the average net realized price (ANRP) was significantly below expectations due to higher patient assistance costs and higher PBM rebate levels than anticipated.  This was a function of lower-than-anticipated adoption rates of the Company’s primary care medicines onto certain healthcare plan formularies (custom clients), resulting in higher patient assistance costs to the Company, as well as fact that PBM plans that covered the Company’s primary care medicines are primarily plans that require a higher rebate (PBM-chosen formulary clients), resulting in higher rebate costs.  To a lesser extent, the lower ANRP in the quarter was also due to a higher rate of managed care control in the Company’s non-contracted business, reflecting an industry-wide trend. PBM clients broadly fall into two categories, clients that follow a PBM-chosen formulary and clients where the PBM works on their behalf to provide customized formularies (custom clients).  Rebate amounts paid to the PBMs for custom clients are typically lower than rebate amounts paid to the PBM for PBM-chosen formulary clients. When the Company established its financial guidance for full-year 2017, the Company estimated the adoption trajectory and mix of PBM clients that the change to its commercial model would generate.  This took into account input from the PBMs.  The Company did not have full visibility into the actual PBM client mix and the magnitude of the difference compared to its assumptions until it received detailed PBM invoices in late April and early May. While the Company continues to work to drive adoption of its medicines with custom clients, it now expects a much lower level of adoption of custom client plans in 2017.  Compared to its previous financial guidance, the Company has incorporated a higher level of rebates, a higher level of patient assistance costs and a lower level of total prescription volume into its full-year 2017 primary care business unit net sales forecast.  It is also reducing certain primary care business unit operating costs as well as other company costs to align its cost structure with revised net sales expectations.  As a result, the Company has lowered its full-year 2017 net sales and adjusted EBITDA guidance. First-Quarter 2017 Financial Results Note:  For additional detail and reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures, please refer to the tables at the end of this release. For the full-year 2017, the Company expects continued strong net sales growth for both its orphan and rheumatology businesses, driven primarily by strong patient growth in KRYSTEXXA, RAVICTI and PROCYSBI.  In its primary care business unit, the Company is assuming net sales of more than $300 million. As a result of these expectations, the Company revised its full-year 2017 net sales guidance range to $1.000 billion to $1.035 billion from $1.240 billion to $1.290 billion.  The Company revised its full-year 2017 adjusted EBITDA guidance to $315 million to $350 million from $525 million to $575 million, which assumes the lower net sales range and accounts for cost reductions, primarily in its primary care business, and a reinvestment of a portion of these reductions in KRYSTEXXA to maximize its long-term potential.  It also reflects an approximate $20 million increase in operating expenses, primarily in R&D, for full-year 2017 related to teprotumumab.  The Company is raising its estimate of peak annual net sales for KRYSTEXXA to $400 million from $250 million. At 7:30 a.m. EST / 12:30 p.m. IST today, the Company will host a live conference call and webcast to review its financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com.  Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the conference call will be available approximately two hours after the call and accessible through one of the following telephone numbers, using the passcode below: About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com.  Follow @HZNPplc on Twitter or view careers on our LinkedIn page. Note Regarding Use of Non-GAAP Financial Measures EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon Pharma as non-GAAP financial measures.  Horizon Pharma provides certain other financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP tax rate and non-GAAP operating cash flow, each of which include adjustments to GAAP figures.  These non-GAAP measures are intended to provide additional information on Horizon Pharma’s performance, operations, expenses, profitability and cash flows.  Adjustments to Horizon Pharma's GAAP figures as well as EBITDA exclude acquisition-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia, an upfront fee for a license of a patent, a litigation settlement, loss on debt extinguishment and loss on sale of long-term investments, costs of debt refinancing, drug manufacturing harmonization costs, as well as non-cash items such as share-based compensation, depreciation and amortization, royalty accretion, non-cash interest expense, intangible and other non-current asset impairment charges, and other non-cash adjustments.  Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred.  Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures.  Horizon Pharma believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon Pharma's financial and operating performance.  The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected 2017 financial results and trends and to facilitate comparisons between periods and with respect to projected information.  In addition, these non-GAAP financial measures are among the indicators Horizon Pharma's management uses for planning and forecasting purposes and measuring the Company's performance.  For example, adjusted EBITDA is used by Horizon Pharma as one measure of management performance under certain incentive compensation arrangements.  These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.  The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.  Horizon Pharma has not provided a reconciliation of its full-year 2017 adjusted EBITDA outlook to an expected net income (loss) outlook because certain items such as acquisition-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably projected due to the significant impact of changes in Horizon Pharma's stock price, the variability associated with the size or timing of acquisitions and other factors.  These components of net income (loss) could significantly impact Horizon Pharma’s actual net income (loss). Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to Horizon Pharma's full-year 2017 net sales and adjusted EBITDA guidance, expected peak annual sales of KRYSEXXA, growth of 2017 ACTIMMUNE net sales and 2017 nets sales of Horizon Pharma’s primary care business unit medicines, expected financial performance in future periods, expected timing of clinical, regulatory and commercial events, including the planned Phase 3 pivotal clinical trial of teprotumumab and anticipated additional clinical trials of ACTIMMUNE in cancer indications, the timing and potential benefits of Horizon Pharma’s acquisition of River Vision, planned reductions in the Company’s primary care operating expenses and increases in R&D investment and KRYSTEXXA commercialization spending, the expected future impact of Horizon Pharma’s primary care business unit PBM contracting commercial model, the expected launch of RAVICTI in Europe, potential market opportunity for Horizon Pharma’s medicines in approved and potential additional indications, potential growth of Horizon Pharma’s medicines and business and other statements that are not historical facts.  These forward-looking statements are based on Horizon Pharma's current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon Pharma’s actual future financial and operating results may differ from its expectations or goals; Horizon Pharma’s ability to grow net sales from existing products; the availability of coverage and adequate reimbursement and pricing from government and third-party payers and risks relating to Horizon Pharma’s ability to successfully implement its business strategies; whether Horizon Pharma is able to realize expected benefits from arrangements with PBMs; risks related to acquisition integration and achieving projected benefits; risks associated with clinical development and regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon Pharma operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon Pharma's filings and reports with the SEC.  Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information.

Loading Rheumatology collaborators
Loading Rheumatology collaborators